Literature DB >> 20434359

Characterization of a discontinuous epitope of the HIV envelope protein gp120 recognized by a human monoclonal antibody using chemical modification and mass spectrometric analysis.

Christine Hager-Braun1, Elisabeth O Hochleitner, Miroslaw K Gorny, Susan Zolla-Pazner, Rachelle J Bienstock, Kenneth B Tomer.   

Abstract

A subset of the neutralizing anti-HIV antibodies recognize epitopes on the envelope protein gp120 of the human immunodeficiency virus. These epitopes are exposed during conformational changes when gp120 binds to its primary receptor CD4. Based on chemical modification of lysine and arginine residues followed by mass spectrometric analysis, we determined the epitope on gp120 recognized by the human monoclonal antibody 559/64-D, which was previously found to be specific for the CD4 binding domain. Twenty-four lysine and arginine residues in recombinant full-length glycosylated gp120 were characterized; the relative reactivities of two lysine residues and five arginine residues were affected by the binding of 559/64-D. The data show that the epitope is discontinuous and is located in the proximity of the CD4-binding site. Additionally, the reactivities of a residue that is located in the secondary receptor binding region and several residues distant from the CD4 binding site were also altered by Ab binding. These data suggest that binding of 559/64-D induced conformational changes which result in altered surface exposure of specific amino acids distant from the CD4-binding site. Consequently, binding of 559/64-D to gp120 affects not only the CD4-binding site, which is recognized as the epitope, but appears to have a global effect on surface exposed residues of the full-length glycosylated gp120.
Copyright © 2010. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20434359      PMCID: PMC3008351          DOI: 10.1016/j.jasms.2010.03.031

Source DB:  PubMed          Journal:  J Am Soc Mass Spectrom        ISSN: 1044-0305            Impact factor:   3.109


  52 in total

1.  Energetics of the HIV gp120-CD4 binding reaction.

Authors:  D G Myszka; R W Sweet; P Hensley; M Brigham-Burke; P D Kwong; W A Hendrickson; R Wyatt; J Sodroski; M L Doyle
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-01       Impact factor: 11.205

2.  Characterization of the tertiary structure of soluble CD4 bound to glycosylated full-length HIVgp120 by chemical modification of arginine residues and mass spectrometric analysis.

Authors:  Christine Hager-Braun; Kenneth B Tomer
Journal:  Biochemistry       Date:  2002-02-12       Impact factor: 3.162

3.  Fine definition of the epitope on the gp41 glycoprotein of human immunodeficiency virus type 1 for the neutralizing monoclonal antibody 2F5.

Authors:  C E Parker; L J Deterding; C Hager-Braun; J M Binley; N Schülke; H Katinger; J P Moore; K B Tomer
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

4.  Mass spectrometric characterization of the glycosylation pattern of HIV-gp120 expressed in CHO cells.

Authors:  X Zhu; C Borchers; R J Bienstock; K B Tomer
Journal:  Biochemistry       Date:  2000-09-19       Impact factor: 3.162

5.  Mutagenic stabilization and/or disruption of a CD4-bound state reveals distinct conformations of the human immunodeficiency virus type 1 gp120 envelope glycoprotein.

Authors:  Shi-Hua Xiang; Peter D Kwong; Rishi Gupta; Carlo D Rizzuto; David J Casper; Richard Wyatt; Liping Wang; Wayne A Hendrickson; Michael L Doyle; Joseph Sodroski
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

6.  Molecular features of the broadly neutralizing immunoglobulin G1 b12 required for recognition of human immunodeficiency virus type 1 gp120.

Authors:  Michael B Zwick; Paul W H I Parren; Erica O Saphire; Sarah Church; Meng Wang; Jamie K Scott; Philip E Dawson; Ian A Wilson; Dennis R Burton
Journal:  J Virol       Date:  2003-05       Impact factor: 5.103

7.  Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41.

Authors:  M B Zwick; A F Labrijn; M Wang; C Spenlehauer; E O Saphire; J M Binley; J P Moore; G Stiegler; H Katinger; D R Burton; P W Parren
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

8.  Oligomeric structure of the human immunodeficiency virus type 1 envelope protein on the virion surface.

Authors:  Rob J Center; Richard D Leapman; Jacob Lebowitz; Larry O Arthur; Patricia L Earl; Bernard Moss
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

9.  A novel human antibody against human immunodeficiency virus type 1 gp120 is V1, V2, and V3 loop dependent and helps delimit the epitope of the broadly neutralizing antibody immunoglobulin G1 b12.

Authors:  Michael B Zwick; Robert Kelleher; Richard Jensen; Aran F Labrijn; Meng Wang; Gerald V Quinnan; Paul W H I Parren; Dennis R Burton
Journal:  J Virol       Date:  2003-06       Impact factor: 5.103

10.  Human monoclonal antibodies specific for conformation-sensitive epitopes of V3 neutralize human immunodeficiency virus type 1 primary isolates from various clades.

Authors:  Miroslaw K Gorny; Constance Williams; Barbara Volsky; Kathy Revesz; Sandra Cohen; Victoria R Polonis; William J Honnen; Samuel C Kayman; Chavdar Krachmarov; Abraham Pinter; Susan Zolla-Pazner
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

View more
  2 in total

1.  Genetic mapping of a highly variable norovirus GII.4 blockade epitope: potential role in escape from human herd immunity.

Authors:  Kari Debbink; Eric F Donaldson; Lisa C Lindesmith; Ralph S Baric
Journal:  J Virol       Date:  2011-11-16       Impact factor: 5.103

Review 2.  Peptide-based vaccinology: experimental and computational approaches to target hypervariable viruses through the fine characterization of protective epitopes recognized by monoclonal antibodies and the identification of T-cell-activating peptides.

Authors:  Matteo Castelli; Francesca Cappelletti; Roberta Antonia Diotti; Giuseppe Sautto; Elena Criscuolo; Matteo Dal Peraro; Nicola Clementi
Journal:  Clin Dev Immunol       Date:  2013-06-26
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.